載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$17.64
+US$0.20 · +1.15%
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
前收盤價
US$17.64
+US$0.20 · +1.15%
盤中時間採用ET。市場資料可能有所延遲。
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
日內區間
目前US$17.64
52週區間
目前US$17.64
盤中時間採用ET。市場資料可能有所延遲。
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
日內區間
目前US$17.64
52週區間
目前US$17.64
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 143億 USD | 147.39億 USD | 154.27億 USD | 162.63億 USD | 178.86億 USD |
| 銷貨成本 | 92.86億 USD | 91.16億 USD | 89.88億 USD | 97.66億 USD | 123.11億 USD |
| 毛利 | 50.14億 USD | 56.24億 USD | 64.39億 USD | 64.97億 USD | 55.76億 USD |
| 研究與開發 | 9.66億 USD | 8.09億 USD | 8.05億 USD | 6.62億 USD | 6.81億 USD |
| 銷售、一般及管理費用 | 37.94億 USD | 44.26億 USD | 46.5億 USD | 41.79億 USD | 45.29億 USD |
| 營業費用 | 76.77億 USD | 56.14億 USD | 56.72億 USD | 48.82億 USD | 56.1億 USD |
| 利息支出 | 4.71億 USD | 5.5億 USD | 5.73億 USD | 5.92億 USD | 6.36億 USD |
| 折舊和攤銷 | 27.98億 USD | 27.09億 USD | 27.41億 USD | 30.28億 USD | 45.07億 USD |
| 營業利益 | −26.63億 USD | 1010萬 USD | 7.66億 USD | 16.15億 USD | −3400萬 USD |
| 淨利 | −35.15億 USD | −6.34億 USD | 5470萬 USD | 20.79億 USD | −12.69億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.17
上漲空間 25.68%年度分割調整後的每股現金分配。
US$0.48
2025年（完整年度）+100.0% 自從 2006
2026年（部分年度）：US$0.36
US$0.24
2,006
US$0.48
2,022
US$0.48
2,023
US$0.48
2,024
US$0.48
2,025
US$0.36
2,026*
* 在現有股息歷史記錄中，該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年8月21日 | US$0.12Quarterly | 2026年8月21日 | 2026年9月16日 |
股息 | 2026年5月22日 | US$0.12Quarterly | 2026年5月22日 | 2026年6月17日 |
股息 | 2026年3月9日 | US$0.12Quarterly | 2026年3月9日 | 2026年3月18日 |
股息 | 2025年11月24日 | US$0.12Quarterly | 2025年11月24日 | 2025年12月15日 |
股息 | 2025年8月22日 | US$0.12Quarterly | 2025年8月22日 | 2025年9月15日 |
股息 | 2025年5月23日 | US$0.12Quarterly | 2025年5月23日 | 2025年6月16日 |
除息 2026年8月21日
US$0.12
Quarterly
2026年8月21日登記 · 支付日 2026年9月16日
除息 2026年5月22日
US$0.12
Quarterly
2026年5月22日登記 · 支付日 2026年6月17日
除息 2026年3月9日
US$0.12
Quarterly
2026年3月9日登記 · 支付日 2026年3月18日
除息 2025年11月24日
US$0.12
Quarterly
2025年11月24日登記 · 支付日 2025年12月15日
除息 2025年8月22日
US$0.12
Quarterly
2025年8月22日登記 · 支付日 2025年9月15日
除息 2025年5月23日
US$0.12
Quarterly
2025年5月23日登記 · 支付日 2025年6月16日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T387.06億0.03%129.35兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI6.12億0.03%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO5.11億0.03%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB4.42億0.24%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR2.81億0.41%682億 USD0.05%US$234.43+0.22%
iShares Core S&P 500 ETFIVV2.66億0.03%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY2.45億0.03%8172億 USD0.09%US$778.57+0.60%
Invesco S&P 500 Equal Weight ETFRSP2.1億0.21%977.83億 USD0.20%US$213.04+0.55%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYInvesco S&P 500 Equal Weight ETFRSPAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
